Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.890
-0.050 (-2.58%)
At close: Mar 3, 2026, 4:00 PM EST
1.890
0.00 (0.00%)
Pre-market: Mar 4, 2026, 6:19 AM EST
Cardiff Oncology Employees
As of December 31, 2025, Cardiff Oncology had 31 total employees, including 30 full-time and 1 part-time employees. The number of employees decreased by 2 or -6.06% compared to the previous year.
Employees
31
Change (1Y)
-2
Growth (1Y)
-6.06%
Revenue / Employee
$19,129
Profits / Employee
-$1,479,871
Market Cap
129.21M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 31 | -2 | -6.06% | 30 | 1 |
| Dec 31, 2024 | 33 | 1 | 3.13% | 32 | 1 |
| Dec 31, 2023 | 32 | 6 | 23.08% | 31 | 1 |
| Dec 31, 2022 | 26 | 3 | 13.04% | 25 | 1 |
| Dec 31, 2021 | 23 | 11 | 91.67% | 22 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Adagene | 138 |
| Artiva Biotherapeutics | 106 |
| Tenaya Therapeutics | 97 |
| Immunic | 90 |
| Connect Biopharma Holdings | 62 |
| Spero Therapeutics | 32 |
| Genelux | 24 |
| Black Diamond Therapeutics | 24 |
CRDF News
- 5 days ago - Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 7 days ago - Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update - GlobeNewsWire
- 12 days ago - Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 5 weeks ago - Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus - Benzinga
- 5 weeks ago - Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript - Seeking Alpha
- 5 weeks ago - Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - GlobeNewsWire
- 5 weeks ago - Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development - GlobeNewsWire
- 7 weeks ago - Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm - Seeking Alpha